Published online before print April 18, 2005, doi: 10.1161/01.HYP.0000165020.14745.79
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;45:907.)
© 2005 American Heart Association, Inc.
Original Articles |
Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome
From the Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Belgium (J.-G.W., J.A.S., R.F.); the Centre for Epidemiological Studies and Clinical Trials (J.-G.W.), Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai, China; the Preventive Cardiology Program, University of California, Irvine (S.S.F.); and the Department of Clinical Pharmacology, Claude Bernard University, Lyon Hospitals, France (F.G.).
Correspondence to Jan A. Staessen, MD, PhD, Studiecoördinatiecentrum, Laboratorium Hypertensie, Campus Gasthuisberg, Gebouw Onderwijs en Navorsing, Herestraat 49, bus 702, B-3000 Leuven, Belgium. E-mail jan.staessen{at}med.kuleuven.ac.be
Based on individual patient data, we performed a quantitative overview of trials in hypertension to investigate to what extent lowering of systolic blood pressure (SBP) and diastolic blood pressure (DBP) contributed to cardiovascular prevention. We selected trials that tested active antihypertensive drugs against placebo or no treatment. Our analyses included 12 903 young (30 to 49 years of age) patients randomized in 3 trials and 14 324 old (60 to 79 years of age) and 1209 very old (
80 years of age) patients enrolled in 8 trials. Antihypertensive treatment reduced SBP/DBP by 8.3/4.6 mm Hg in young patients, by 10.7/4.2 mm Hg in old patients, and by 9.4/3.2 mm Hg in very old patients, respectively, resulting in ratios of DBP to SBP lowering of 0.55, 0.39, and 0.32, respectively (P=0.004 for trend with age). In spite of the differential lowering of SBP and DBP, antihypertensive treatment reduced the risk of all cardiovascular events, stroke and myocardial infarction in the 3 age strata to a similar extent. Absolute benefit increased with age and with lower ratio of DBP to SBP lowering. Furthermore, in patients with a larger-than-median reduction in SBP, active treatment consistently reduced the risk of all outcomes irrespective of the decrease in DBP or the achieved DBP. These findings remained consistent if the achieved DBP averaged <70 mm Hg. In conclusion, our overview suggests that antihypertensive drug treatment improves outcome mainly through lowering of SBP.
Key Words: clinical trials • blood pressure • meta-analysis
This article has been cited by other articles:
 |
|
 |
|
  B. Williams Hypertension and the "J-curve". J. Am. Coll. Cardiol., November 10, 2009; 54(20): 1835 - 1836. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, R. D. Feldman, K. Wyard, R. Brant, N. R.C. Campbell, and for the CHEP Outcomes Research Task Force The impact of the Canadian Hypertension Education Programme in its first decade Eur. Heart J., June 2, 2009; 30(12): 1434 - 1439. [Full Text] [PDF]
|
|
|
|
|
|
S. Bangalore, F. H. Messerli, S. S. Franklin, G. Mancia, A. Champion, and C. J. Pepine Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis Eur. Heart J., June 1, 2009; 30(11): 1395 - 1401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Mistry, A. L. Maes, K. C. Lasseter, M. J. Davies, K. M. Gottesdiener, J. A. Wagner, and G. A. Herman Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension J. Clin. Pharmacol., May 1, 2008; 48(5): 592 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Fagard, J. A. Staessen, L. Thijs, H. Celis, C. J. Bulpitt, P. W. de Leeuw, G. Leonetti, J. Tuomilehto, and Y. Yodfat On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension Arch Intern Med, September 24, 2007; 167(17): 1884 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tatasciore, G. Renda, M. Zimarino, M. Soccio, G. Bilo, G. Parati, G. Schillaci, and R. De Caterina Awake Systolic Blood Pressure Variability Correlates With Target-Organ Damage in Hypertensive Subjects Hypertension, August 1, 2007; 50(2): 325 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Roman, R. B. Devereux, J. R. Kizer, E. T. Lee, J. M. Galloway, T. Ali, J. G. Umans, and B. V. Howard Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial Pressure: The Strong Heart Study Hypertension, July 1, 2007; 50(1): 197 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Wang, Y. Li, S. S. Franklin, and M. Safar Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview Hypertension, July 1, 2007; 50(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y.H. Lip, L. Frison, M. Grind, and on behalf of the SPORTIF Investigators Effect of hypertension on anticoagulated patients with atrial fibrillation Eur. Heart J., March 2, 2007; 28(6): 752 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Segura, J. A. Garcia-Donaire, M. Praga, and L. M. Ruilope Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S136 - S140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kaplan An Updated Meta-Analysis With a Few Surprises Hypertension, August 1, 2005; 46(2): 257 - 258. [Full Text] [PDF]
|
|